L. Peyrin-biroulet, A. Cieza, and W. Sandborn, Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health, Gut, vol.61, issue.2, pp.241-248, 2012.
DOI : 10.1136/gutjnl-2011-300049

URL : https://hal.archives-ouvertes.fr/hal-00683081

R. Watson and V. Preedy, Bioactive Food as Dietary Interventions for Liver and Gastrointestinal Disease, 2013.

S. Thaul, How FDA Approves Drugs and Regulates Their Safety and Effectiveness, 2012.

B. Sands, S. Katz, D. Wolf, and B. Feagan, A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease, Gut, vol.38, issue.Suppl 8, pp.1288-94, 2013.
DOI : 10.2169/internalmedicine.38.102

W. Stack, D. Jenkins, and P. Vivet, Lack of effectiveness of the platelet-activating factor antagonist SR27417A in patients with active ulcerative colitis: A randomized controlled trial, Gastroenterology, vol.115, issue.6, pp.1340-1345, 1998.
DOI : 10.1016/S0016-5085(98)70011-3

D. Price, E. Hillyer, and T. Van-der-molen, Efficacy versus effectiveness trials, Current Opinion in Allergy and Clinical Immunology, vol.13, issue.1, pp.50-57, 2013.
DOI : 10.1097/ACI.0b013e32835ad059

H. El-serag, J. Talwalkar, and W. Kim, Efficacy, effectiveness, and comparative effectiveness in liver disease, Hepatology, vol.361, issue.2, pp.403-410, 2010.
DOI : 10.1056/NEJMp0904133

J. Concato, N. Shah, and R. Horwitz, Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs, New England Journal of Medicine, vol.342, issue.25, pp.1887-92, 2000.
DOI : 10.1056/NEJM200006223422507

A. Singal, P. Higgins, and A. Waljee, A Primer on Effectiveness and Efficacy Trials, Clinical and Translational Gastroenterology, vol.59, issue.1, p.45, 2014.
DOI : 10.1016/j.jclinepi.2006.01.011

C. Ha, T. Ullman, and C. Siegel, Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population, Clinical Gastroenterology and Hepatology, vol.10, issue.9, pp.1002-1009, 2012.
DOI : 10.1016/j.cgh.2012.02.004

R. Akehurst and E. Kaltenthaler, Treatment of irritable bowel syndrome: a review of randomised controlled trials, Gut, vol.48, issue.2, pp.272-82, 2001.
DOI : 10.1136/gut.48.2.272

J. Concato, Observationalversus experimental studies: What???s the evidence for a hierarchy?, NeuroRX, vol.137, issue.3, pp.341-348, 2004.
DOI : 10.7326/0003-4819-137-5_Part_1-200209030-00015

E. Cox, B. Martin, V. Staa, and T. , Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report???Part II, Value in Health, vol.12, issue.8, pp.1053-61, 2009.
DOI : 10.1111/j.1524-4733.2009.00601.x

M. Viswanathan, N. Berkman, D. Dryden, and L. Hartling, Assessing risk of bias and confounding in observational studies of interventions or exposures: further development of the RTI Item Bank, ]: Agency for Healthcare Research and Quality, 2013.

N. Pearce and S. Greenland, Confounding and interaction, Handbook of Epidemiology, 2005.

N. Dreyer, S. Schneeweiss, and B. Mcneil, GRACE principles: recognizing high-quality observational studies of comparative effectiveness, Am J Manag Care, vol.16, pp.467-71, 2010.

J. Ellenberg, Selection bias in observational and experimental studies, Statistics in Medicine, vol.86, issue.5-7, pp.557-67, 1994.
DOI : 10.1161/01.STR.19.5.547

P. Lakatos, P. Golovics, and G. David, Has There Been a Change in the Natural History of Crohn's Disease? Surgical Rates and Medical Management in a Population-Based Inception Cohort from Western Hungary Between 1977???2009, The American Journal of Gastroenterology, vol.31, issue.4, pp.579-88, 1977.
DOI : 10.1016/j.dld.2008.09.010

C. Rungoe, E. Langholz, and M. Andersson, Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979???2011, Gut, vol.135, issue.(7 Suppl), pp.1607-1623, 1979.
DOI : 10.1053/j.gastro.2008.06.079

E. Krishnan, K. Murtagh, B. Bruce, D. Cline, G. Singh et al., Attrition bias in rheumatoid arthritis databanks: a case study of 6346 patients in 11 databanks and 65,649 administrations of the Health Assessment Questionnaire, J Rheumatol, vol.31, pp.1320-1326, 2004.

G. Lichtenstein, B. Feagan, and R. Cohen, Serious Infections and Mortality in Association With Therapies for Crohn???s Disease: TREAT Registry, Clinical Gastroenterology and Hepatology, vol.4, issue.5, pp.621-651, 2006.
DOI : 10.1016/j.cgh.2006.03.002

M. Berger, M. Mamdani, and D. Atkins, Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report???Part I, Value in Health, vol.12, issue.8, pp.1044-1052, 2009.
DOI : 10.1111/j.1524-4733.2009.00600.x

M. Johnson, W. Crown, and B. Martin, Good Research Practices for Comparative Effectiveness Research: Analytic Methods to Improve Causal Inference from Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report???Part III, Value in Health, vol.12, issue.8, pp.1062-1073, 2009.
DOI : 10.1111/j.1524-4733.2009.00602.x

S. Schneeweiss, On Guidelines for Comparative Effectiveness Research Using Nonrandomized Studies in Secondary Data Sources, Value in Health, vol.12, issue.8, p.1041, 2009.
DOI : 10.1111/j.1524-4733.2009.00607.x

D. Moher, K. Schulz, and D. Altman, The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized Trials, JAMA, vol.285, issue.15, pp.1987-91, 2001.
DOI : 10.1001/jama.285.15.1987

V. Elm, E. Altman, D. Egger, and M. , Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies, BMJ, vol.335, issue.7624, pp.806-814, 2007.
DOI : 10.1136/bmj.39335.541782.AD

W. Sandborn, B. Feagan, and S. Hanauer, A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease, Gastroenterology, vol.122, issue.2, pp.512-542, 2002.
DOI : 10.1053/gast.2002.31072

S. Mazzuoli, F. Guglielmi, E. Antonelli, M. Salemme, G. Bassotti et al., Definition and evaluation of mucosal healing in clinical practice, Digestive and Liver Disease, vol.45, issue.12, pp.969-77, 2013.
DOI : 10.1016/j.dld.2013.06.010

A. Annaházi and T. Molnár, Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal, Gastroenterology Research and Practice, vol.25, issue.10, p.832395, 2015.
DOI : 10.3748/wjg.v18.i36.5058

D. Rubin and R. Little, Statistical Analysis with Missing Data, 2002.

L. Fisher and K. Patil, MATCHING AND UNRELATEDNESS, American Journal of Epidemiology, vol.100, issue.5, pp.347-356, 1974.
DOI : 10.1093/oxfordjournals.aje.a112043

S. Greenland, J. Pearl, and J. Robins, Causal Diagrams for Epidemiologic Research, Epidemiology, vol.10, issue.1, pp.37-48, 1999.
DOI : 10.1097/00001648-199901000-00008

M. Waterman, W. Xu, and A. Dinani, Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease, Gut, vol.62, issue.3, pp.387-94, 2013.
DOI : 10.1136/gutjnl-2011-301495

P. Rosenbaum and D. Rubin, The central role of the propensity score in observational studies for causal effects, Biometrika, vol.70, issue.1, pp.41-55, 1983.
DOI : 10.1093/biomet/70.1.41

M. Brookhart, S. Schneeweiss, K. Rothman, R. Glynn, J. Avorn et al., Variable Selection for Propensity Score Models, American Journal of Epidemiology, vol.163, issue.12, pp.1149-56, 2006.
DOI : 10.1093/aje/kwj149

P. Juillerat, S. Schneeweiss, E. Cook, A. Ananthakrishnan, H. Mogun et al., Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, vol.19, issue.3, pp.239-286, 2012.
DOI : 10.1002/pds.1926

D. Rubin, Estimating Causal Effects from Large Data Sets Using Propensity Scores, Annals of Internal Medicine, vol.127, issue.8_Part_2, pp.757-63, 1997.
DOI : 10.7326/0003-4819-127-8_Part_2-199710151-00064

D. Rubin, Multiple Imputation for Nonresponse in Surveys, 1987.
DOI : 10.1002/9780470316696

C. Forrest, W. Crandall, and L. Bailey, Effectiveness of Anti-TNF?? for Crohn Disease: Research in a Pediatric Learning Health System, PEDIATRICS, vol.134, issue.1, pp.37-44, 2014.
DOI : 10.1542/peds.2013-4103

A. Rencher and W. Christensen, Methods of Multivariate Analysis, 2012.

P. Peduzzi, J. Concato, A. Feinstein, and T. Holford, Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates, Journal of Clinical Epidemiology, vol.48, issue.12, pp.1503-1513, 1995.
DOI : 10.1016/0895-4356(95)00048-8

D. Agostino and R. , Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group, Statistics in Medicine, vol.17, issue.19, pp.2265-81, 1998.
DOI : 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B

L. Peyrin-biroulet, A. Oussalah, N. Williet, C. Pillot, L. Bresler et al., Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease, Gut, vol.60, issue.7, pp.930-936, 2011.
DOI : 10.1136/gut.2010.227884

T. Therneau and P. Grambsch, Modeling Survival Data: Extending the Cox Model, 2000.
DOI : 10.1007/978-1-4757-3294-8

G. Vernier-massouille, M. Balde, and J. Salleron, Natural History of Pediatric Crohn's Disease: A Population-Based Cohort Study, Gastroenterology, vol.135, issue.4, pp.1106-1119, 2008.
DOI : 10.1053/j.gastro.2008.06.079

T. Scheike and T. Martinussen, On Estimation and Tests of Time-Varying Effects in the Proportional Hazards Model, Scandinavian Journal of Statistics, vol.88, issue.1, pp.51-62, 2004.
DOI : 10.1023/A:1015849821021

W. Cochran, The Effectiveness of Adjustment by Subclassification in Removing Bias in Observational Studies, Biometrics, vol.24, issue.2, pp.295-313, 1968.
DOI : 10.2307/2528036

S. Yusuf, J. Wittes, J. Probstfield, and H. Tyroler, Analysis and Interpretation of Treatment Effects in Subgroups of Patients in Randomized Clinical Trials, JAMA: The Journal of the American Medical Association, vol.266, issue.1, pp.93-101, 1991.
DOI : 10.1001/jama.1991.03470010097038

B. Dijkman, B. Kooistra, and M. Bhandari, How to work with a subgroup analysis, Can J Surg, vol.52, pp.515-537, 2009.

S. Brookes, E. Whitely, M. Egger, D. Smith, G. Mulheran et al., Subgroup analyses in randomized trials: risks of subgroup-specific analyses;, Journal of Clinical Epidemiology, vol.57, issue.3, pp.229-265, 2004.
DOI : 10.1016/j.jclinepi.2003.08.009

S. Lord, V. Gebski, and A. Keech, Multiple analyses in clinical trials: sound science or data dredging?, Med J Aust, vol.181, pp.452-456, 2004.

L. Beaugerie, N. Brousse, and A. Bouvier, Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study, The Lancet, vol.374, issue.9701, pp.1617-1642, 2009.
DOI : 10.1016/S0140-6736(09)61302-7

URL : https://hal.archives-ouvertes.fr/hal-00466312

S. Travis, S. Danese, and L. Kupcinskas, Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study, Gut, vol.142, issue.Suppl 1, pp.433-474, 2014.
DOI : 10.1016/S0016-5085(12)63046-7